Skip to main content
Journal cover image

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.

Publication ,  Journal Article
Siena, S; Sartore-Bianchi, A; Marsoni, S; Hurwitz, HI; McCall, SJ; Penault-Llorca, F; Srock, S; Bardelli, A; Trusolino, L
Published in: Ann Oncol
May 1, 2018

Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver, and a well-established therapeutic target in breast and gastric cancers. Using functional and genomic analyses of patient-derived xenografts, we previously showed that a subset (approximately 5%) of metastatic colorectal cancer (CRC) tumors is driven by amplification or mutation of HER2. This paper reviews the role of HER2 amplification as an oncogenic driver, a prognostic and predictive biomarker, and a clinically actionable target in CRC, considering the specifics of HER2 testing in this tumor type. While the role of HER2 as a biomarker for prognosis in CRC remains uncertain, its relevance as a therapeutic target has been established. Indeed, independent studies documented substantial clinical benefit in patients treated with biomarker-driven HER2-targeted therapies, with an impact on response rates and duration of response that compared favorably with immunotherapy and other examples of precision oncology. HER2-targeted therapeutic strategies have the potential to change the treatment paradigm for a clinically relevant subgroup of metastatic CRC patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

May 1, 2018

Volume

29

Issue

5

Start / End Page

1108 / 1119

Location

England

Related Subject Headings

  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Progression-Free Survival
  • Prognosis
  • Precision Medicine
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Neoadjuvant Therapy
  • Molecular Targeted Therapy
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Siena, S., Sartore-Bianchi, A., Marsoni, S., Hurwitz, H. I., McCall, S. J., Penault-Llorca, F., … Trusolino, L. (2018). Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol, 29(5), 1108–1119. https://doi.org/10.1093/annonc/mdy100
Siena, S., A. Sartore-Bianchi, S. Marsoni, H. I. Hurwitz, S. J. McCall, F. Penault-Llorca, S. Srock, A. Bardelli, and L. Trusolino. “Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.Ann Oncol 29, no. 5 (May 1, 2018): 1108–19. https://doi.org/10.1093/annonc/mdy100.
Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018 May 1;29(5):1108–19.
Siena, S., et al. “Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.Ann Oncol, vol. 29, no. 5, May 2018, pp. 1108–19. Pubmed, doi:10.1093/annonc/mdy100.
Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, Srock S, Bardelli A, Trusolino L. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018 May 1;29(5):1108–1119.
Journal cover image

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

May 1, 2018

Volume

29

Issue

5

Start / End Page

1108 / 1119

Location

England

Related Subject Headings

  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Progression-Free Survival
  • Prognosis
  • Precision Medicine
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Neoadjuvant Therapy
  • Molecular Targeted Therapy
  • Humans